Actinium Pharmaceuticals, Inc.
501 Fifth Avenue
New York City
New York
10017
United States
Tel: 646-459-4201
270 articles with Actinium Pharmaceuticals, Inc.
-
Here’s a look at some of the stories that emerged from the conference on Wednesday.
-
Actinium and Astellas Announce Research Collaboration Focused on Novel Actinium-225 Based Targeted Radiotherapies
1/13/2021
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced the research collaboration with Astellas Pharma Inc. (TSE:4503) ("Astellas") to develop novel targeted radiotherapies using its Antibody Warhead Enabling (AWE) technology platform.
-
Actinium Announces Successful Pre-Planned Ad Hoc Interim Analysis of Phase 3 SIERRA trial
12/29/2020
- 100% rate of BMT and engraftment in patients receiving therapeutic dose of Iomab-B and lower rates of sepsis and sepsis related Grade ≥3 adverse events compared to patients receiving salvage therapies at 75% enrollment recently highlighted in oral presentations at ASH 2020 Annual Meeting - Independent Data Monitoring Committee recommends SIERRA continue as planned to full enrollment of 150 patients; trial is currently over 75% enrolled
-
Actinium Announces Positive Interim Results from Iomab-B Pivotal Phase 3 SIERRA Trial at 75% of Total Patient Enrollment at the 62nd American Society of Hematology Annual Meeting
12/7/2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that interim data from its ongoing pivotal Phase 3 trial in patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML) were presented in an oral presentation at the 62nd American Society of Hematology (ASH) annual meeting
-
Actinium Highlights Iomab-B Safety Data Presented at the 62nd American Society of Hematology Annual Meeting
12/7/2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today announced that safety data from its ongoing pivotal Phase 3 SIERRA trial of Iomab-B in patients with relapsed or refractory Acute Myeloid Leukemia (R/R AML) were presented at the 2020 American Society of Hematology (ASH) annual meeting.
-
Actinium Presents Interim Data from Actimab-A CLAG-M Phase 1 Combination Trial at the 62nd American Society of Hematology Annual Meeting
12/7/2020
100% remission rate in the third dose cohort of 0.75 μCi/kg of Actimab-A (lintuzumab-225Ac) and standard regimen of CLAG-M
-
Actinium Highlights Clinical Data to be Presented at the Upcoming 62nd American Society of Hematology Annual Meeting
12/3/2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today highlighted that four abstracts detailing the Company's clinical trials for Iomab-B and Actimab-A will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting, which is being held virtually December 5-8, 2020.
-
Actinium Appoints Mary Mei Chen, M.D., Ph.D. as Vice President of Clinical Development
12/1/2020
Dr. Chen brings over twenty years of clinical research and development experience; including executing global registrational trials in relapsed and refractory AML
-
Actinium Highlights Foundational Patents Covering the Composition of Apamistamab Antibody and Iomab-B Antibody Radiation Conjugate for Targeted Conditioning Until 2037 and Recent EU Patent Activity
11/23/2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium" or the "Company") today highlighted its intellectual property portfolio for apamistamab, a CD45 targeting antibody, and the Antibody Radiation Conjugate (ARC) comprised of apamistamab and the radioisotope iodine-131 used in the Company's lead Phase 3 candidate, Iomab-B, and its Iomab-ACT programs
-
Actinium Strengthens Leadership Team with Appointment of Dr. Avinash Desai as Executive Vice President of Clinical Development, Operations and Medical Affairs
11/19/2020
- Dr. Desai has over twenty-five years of hematology and oncology-focused clinical development and medical affairs experience, including the successful launches of targeted therapies, monoclonal antibodies, and PARP inhibitors
-
Actinium to Participate in the Alliance Global Partners' Virtual Healthcare Symposium
11/16/2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will be participating in the Alliance Global Partners' Virtual Healthcare Symposium being held on Thursday, November 19, 2020 . During the event, Actinium's Chief Medical Officer Mark Berger will participate in a panel discussing emerging tre
-
Actinium to Host KOL Call on November 11th Featuring Actimab-A AML Combination Trials
11/11/2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that it will host a CD33 program update featuring two key opinion leaders (KOLs) today, November 11th at 4:15 PM ET
-
100% Remission Rate Reported in Third Dose Cohort of Actimab-A CLAG-M Phase 1 Combination Trial in Patients with Relapsed or Refractory AML
11/4/2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that 100% of evaluable patients in the third and planned final dose cohort of the Actimab-A CLAG-M Phase 1 trial being conducted at the Medical College of Wisconsin (MCW) achieved remission.
-
Actinium Announces Two Oral Presentations Featuring Data and Findings from the Phase 3 SIERRA Trial of Iomab-B at the 62nd American Society of Hematology Annual Meeting
11/4/2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that two abstracts on the Company's Antibody Radiation Conjugate (ARC) Iomab-B were accepted for oral presentations at the 2020 American Society of Hematology (ASH) annual meeting that is being held virtually December 5-8, 2020.
-
Actinium Announces Actimab-A Venetoclax First-in-Human Data Accepted for Poster Presentation at the 62nd American Society of Hematology Annual Meeting
11/4/2020
Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) ("Actinium") today announced that data from the Phase 1 portion of the Actimab-A venetoclax Phase 1/2 combination trial, has been accepted for poster presentation at the 2020 American Society of Hematology (ASH) annual meeting that is being held virtually December 5-8, 2020.
-
Actinium Pharmaceuticals, Inc. Provides Corporate Update and Year-End 2020 Outlook
10/28/2020
- Multiple milestones expected in the Fourth Quarter from the Company's ARC pipeline including Phase 3 data from the pivotal SIERRA trial for Iomab-B and Actimab-A combination trials with CLAG-M and venetoclax - Ad hoc interim analysis from SIERRA to be completed by year end
-
Actinium Pharmaceuticals, Inc. Awarded Grant by National Institutes of Health to Study Novel Iomab-ACT Targeted Conditioning with a CD19 CAR T-Cell Therapy
10/21/2020
NIH grant to support first of its kind clinical trial to use Antibody Radio-Conjugate for targeted conditioning prior to CAR T-cell therapy in patients with acute lymphoblastic leukemia and diffuse large B-cell lymphoma
-
Actinium Pharmaceuticals, Inc. Expands R&D Capabilities with New Research Facility to Enhance Development of Next Generation Antibody Radiation Conjugates Leveraging Its Proprietary AWE Platform
10/14/2020
Actinium Pharmaceuticals, Inc. announced the launch of its new research and development lab facility in New York City.
-
Actinium Pharmaceuticals, Inc. Announces Clinical Trial Site Expansion in its Multi-Center Phase 1/2 Actimab-A Venetoclax Combination Trial
10/6/2020
Actinium Pharmaceuticals, Inc. announced that the University of Louisville and the Ochsner Clinic in New Orleans, Louisiana are now active trial sites in its Phase 1/2 Actimab-A venetoclax combination trial for patients with Relapsed or Refractory Acute Myeloid Leukemia age 18 and above.
-
Actinium Pharmaceuticals Successfully Completes First Dosing Cohort in the Phase 1 Study of Actimab-A and Venetoclax Combination Therapy in Relapsed/Refractory AML Patients
9/23/2020
Combination trial, led by UCLA Medical Center and Principal Investigator Gary Shiller, MD, supported by mechanistic rationale and demonstrated synergy of combining venetoclax with targeted radiation from Actimab-A in preclinical studies